SCHEDULE 13G/A: BlackRock Discloses 5.1% Stake in Enliven Therapeutics

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Enliven Therapeutics Inc., holding 2,941,395 shares of common stock as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in ENLIVEN THERAPEUTICS INC.
• As of June 30, 2025, BlackRock beneficially owned an aggregate of 2,941,395 shares of ENLIVEN THERAPEUTICS INC common stock.
• This ownership represents 5.1% of the total outstanding common stock of ENLIVEN THERAPEUTICS INC.
• BlackRock holds sole voting power over 2,885,529 shares and sole dispositive power over 2,941,395 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While a 13G is a factual disclosure, a significant stake by a major institutional investor like BlackRock can be perceived as a positive signal of confidence in the company, even if it's a passive investment.

Positives

• BlackRock, a major institutional investor, holds a significant 5.1% stake in Enliven Therapeutics Inc., which may signal confidence in the company's prospects.

Risks

• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer of the securities.

Future Outlook

The document is a factual disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant institutional investment by BlackRock in Enliven Therapeutics Inc., a common occurrence in the financial markets where large asset managers take passive stakes in publicly traded companies. It reflects BlackRock's portfolio allocation decisions rather than specific industry trends for Enliven Therapeutics.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for institutional investors acquiring more than 5% of a company's stock.
• BlackRock's 5.1% stake in Enliven Therapeutics Inc. is a typical passive investment size for a large asset manager, comparable to similar stakes held by other major investment firms like Vanguard or State Street in various publicly traded companies across different sectors, including biotechnology or pharmaceuticals, where Enliven Therapeutics operates.

Stakeholder Impact

• Shareholders: May view BlackRock's significant stake as a positive indicator of institutional confidence.

Next Steps

• No specific future actions or milestones for the issuer are mentioned in this beneficial ownership filing.

Key Dates

Recommendation

Keywords

BlackRock, ENLIVEN THERAPEUTICS INC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, ELVN